Added benefits of drospirenone for compliance

Climacteric

Volumn 8, Issue SUPPL. 3, 2005, Pages 28-34

  Foidart, J M ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Drospirenone; Hormone replacement therapy; Oral contraceptive; Premenstrual dysphoric disorder; Premenstrual Syndrome; Women's Health Questionnaire

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE; DROSPIRENONE PLUS ESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT;

BLOATING; BLOOD PRESSURE; BODY WEIGHT; BREAST TENSION; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; EDEMA; FATIGUE; FLUID RETENTION; HORMONE SUBSTITUTION; HUMAN; MENSTRUAL CYCLE; PATIENT COMPLIANCE; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SIDE EFFECT; SKIN DISEASE; STATISTICAL SIGNIFICANCE; TREATMENT WITHDRAWAL; WEIGHT GAIN;

ALDOSTERONE ANTAGONISTS; ANDROSTENES; BODY WEIGHT; CONTRACEPTIVES, ORAL; DRUG COMBINATIONS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PATIENT COMPLIANCE; PREMENSTRUAL SYNDROME; PROGESTERONE CONGENERS; QUALITY OF LIFE;

EID: 27744585626     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130500330309     Document Type: Review

References (24)

1. Apter D, Borsos A, Baumgartner W, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 2003;8:37-51
2. Fuchs N, Prinz H, Koch U. Attitudes to current oral contraceptive use and future developments: the women's perspective. Eur J Contracept Reprod Health Care 1996;1:275-84
3. Rosenberg MJ, Long SC. Oral contraceptives and cycle control: a critical review of the literature. Adv Contracept 1992;8(Suppl 1):35-45
4. Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996;61:166-71
5. Foidart JM. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects. Eur J Contracept Reprod Health Care 2000;5(Suppl 3):25-33
6. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000;5:25-34
7. van Seumeren. Weight gain and hormone replacement therapy: are women's fears justified? Maturitas 2000;34(Suppl 1):S3-8
8. Strothmann A, Schneider HP. Hormone therapy: the European women's perspective. Climacteric 2003;6:337-46
9. Archer DF, Thorneycroft IH, Foegh M, et al. Efficacy and safety of drospirenone-estradiol for hormone therapy: a randomized multicenter trial. Menopause 2005; in press
10. Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001;10:561-9
11. Barnhart KT, Freeman EW, Sondheimer SJ. A clinician's guide to the premenstrual syndrome. Med Clin North Am 1995;79:1457-72
12. Steiner M, Pearlstein T. Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry 2000;61(Suppl 12):17-21
13. Freeman EW. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder. Eur J Contracept Reprod Health Care 2002;7(Suppl 3):27-34; discussion 42-3
14. Endicott J, Amsterdam J, Eriksson E, et al. Is premenstrual dysphoric disorder a distinct clinical entity? J Womens Health Gend Based Med 1999;8:663-79
15. Warner P, Bancroft J. Factors related to self-reporting of the pre-menstrual syndrome. Br J Psychiatry 1990;157:249-60
16. Harding CM, Vail C, Brown R. Effect of oral contraceptives and some psychological factors on the menstrual experience. J Biosoc Sci 1985;17:291-304
17. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992;36:257-66
18. Backstrom T, Hansson-Malmstrom Y, Lindhe BA, Cavalli-Bjorkman B, Nordenstrom S. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception 1992;46:253-68
19. Bancroft J, Rennie D. The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving and other symptoms. J Psychosom Res 1993;37:195-202
20. Graham CA, Sherwin BB. The relationship between retrospective premenstrual symptom reporting and present oral contraceptive use. J Psychosom Res 1987;31:45-53
21. Marriott A, Faragher EB. An assessment of psychological state associated with the menstrual cycle in users of oral contraception. J Psychosom Res 1986;30:41-7
22. Borenstein J, Yu HT, Wade S, Chiou CF, Rapkin A. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med 2003;48:79-85
23. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000;61:105-11
24. Hunter MS. The Women's Health Questionnaire (WHQ): frequently asked questions (FAQ). Health Qual Life Outcomes 2003;1:41